-

CHEMOCENTRYX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ChemoCentryx, Inc. - CCXI

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ChemoCentryx, Inc. (NasdaqGS: CCXI).

On May 4, 2021, the U.S. Food and Drug Administration (the “FDA”) issued briefing documents regarding the New Drug Application for the Company’s drug candidate, avacopan, In the disclosure, the FDA noted that “[c]omplexities of the study design…raise questions about the interpretability of the data to define a clinically meaningful benefit of avacopan” and that the review had “identified several areas of concern, raising uncertainty about the interpretability of the data and the clinical meaningfulness of these results.”

Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information in violation of federal securities laws, which remains ongoing.

KSF’s investigation is focusing on whether ChemoCentryx’s officers and/or directors breached their fiduciary duties to the Company’s shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of ChemoCentryx shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-ccxi/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contacts

Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

Kahn Swick & Foti, LLC

NASDAQ:CCXI

Release Versions

Contacts

Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

More News From Kahn Swick & Foti, LLC

Trade Desk Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of The Trade Desk, Inc. - TTD

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into The Trade Desk, Inc. (“Trade Desk” or the “Company”) (NasdaqGM: TTD). On February 12, 2025, the Company announced its financial results for the fourth quarter and full year of 2024, disclosing 4Q 2024 revenue of $741 million - below its previously issued guidance of $756...

Fortinet Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fortinet Inc. - FTNT

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Fortinet Inc. (the “Company”) (NasdaqGS: FTNT). On August 6, 2025, the Company disclosed disappointing second-quarter 2025 financial results, including that it was already “approximately 40% to 50% of the way through the 2026 upgrade cycle at the end of the second qu...

Corcept 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) (“Corcept” or the “Company”), if they purchased or otherwise acquired the Company’s shares between October 31, 2024 and December 30, 2025, inclusive (the “Cl...
Back to Newsroom